NASDAQ:GRAY Graybug Vision (GRAY) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free GRAY Stock Alerts $5.49 +0.90 (+19.61%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$4.10▼$5.8050-Day Range$3.46▼$4.8552-Week Range$5.00▼$22.12Volume76,715 shsAverage Volume2,165 shsMarket Capitalization$8.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial Media Get Graybug Vision alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Graybug Vision Stock (NASDAQ:GRAY)Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.Read More GRAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRAY Stock News HeadlinesJanuary 4, 2024 | forbes.comBest Vision Insurance Companies Of 2024December 22, 2023 | 9to5mac.comBloomberg: Vision Pro production moving at full speed, February launch plannedApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.November 14, 2023 | usatoday.comBest vision insurance companies of November 2023August 3, 2023 | markets.businessinsider.comComplement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical OfficerJune 10, 2023 | appleinsider.comApple Vision Pro $3,499 mixed-reality headset launches at WWDC after years of rumorsMarch 28, 2023 | marketwatch.comOcular Drug Delivery Technology Market Outlook By 2031March 22, 2023 | finanznachrichten.deGraybug Vision, Inc. Announces Name and Trading Symbol ChangeApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 21, 2023 | finanznachrichten.deGraybug Vision, Inc.: Graybug Announces Name and Trading Symbol ChangeMarch 21, 2023 | benzinga.comGraybug Vision Stock (NASDAQ:GRAY), DividendsMarch 20, 2023 | finance.yahoo.comCalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private PlacementMarch 20, 2023 | finance.yahoo.comIndividual investors are Graybug Vision, Inc.'s (NASDAQ:GRAY) biggest owners and were hit after market cap dropped US$31mMarch 20, 2023 | finance.yahoo.comGraybug Announces Name and Trading Symbol ChangeFebruary 27, 2023 | marketwatch.comOcular Drug Delivery Technology Market is Booming Worldwide with Top Countries DataFebruary 14, 2023 | businesswire.comGRAYBUG VISION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graybug Vision, Inc. - GRAYFebruary 9, 2023 | finanznachrichten.deDelveInsight Business Research, LLP: The Global Ocular Drug Delivery System Market to Register Growth at a CAGR of ~7% by 2027 | DelveInsightFebruary 9, 2023 | yahoo.comThe Global Ocular Drug Delivery System Market to Register Growth at a CAGR of ~7% by 2027 | DelveInsightJanuary 25, 2023 | seekingalpha.comGRAY Graybug Vision, Inc.December 6, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, GRAY, APEN, SALDecember 5, 2022 | wsj.comINVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Graybug Vision, Inc. - GRAYNovember 24, 2022 | benzinga.comGRAYBUG VISION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graybug Vision, Inc. - GRAYNovember 22, 2022 | marketwatch.comGRAY STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Graybug Vision, Inc. Is Fair to ShareholdersNovember 22, 2022 | marketwatch.comGraybug Vision Shares Fall Premarket on CalciMedica Tie-Up >GRAYNovember 22, 2022 | benzinga.comShareholder Alert: Ademi LLP investigates whether Graybug Vision, Inc. has entered into a Fair Transaction with CalciMedicaNovember 22, 2022 | finance.yahoo.comGraybug Vision Agrees To Merge With Inflammatory Disease-Focused BiopharmaNovember 22, 2022 | finanznachrichten.deGraybug Vision, Inc.; CalciMedica Inc.: Graybug and CalciMedica Enter into Definitive Merger AgreementSee More Headlines Receive GRAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Graybug Vision and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GRAY CUSIPN/A CIK1534133 Webwww.graybug.com PhoneN/AFaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($24.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-77.61% Return on Assets-71.34% Debt Debt-to-Equity RatioN/A Current Ratio10.73 Quick Ratio10.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book3.29Miscellaneous Outstanding Shares1,571,000Free Float20,250,000Market Cap$8.62 million OptionableNot Optionable Beta1.20 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Frederic Guerard Pharm.D. (Age 49)Pres, CEO, Sec. & Director Comp: $931.02kMr. Robert S. Breuil (Age 60)CFO & Treasurer Comp: $577.47kDr. Gerald D. Cagle Ph.D. (Age 78)Sr. Advisor & Head of Bus. Devel. Comp: $44.67kDr. Parisa Zamiri M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $662.11kDr. Peter A. Campochiaro M.D.Co-FounderDr. Peter J. McDonnell M.D. (Age 63)Co-Founder Ms. Bettina MaunzChief People Officer & Head of CommunicationsMr. Ming YangSr. VP of R&DDr. Ward M. Peterson Ph.D.Sr. VP of Preclinical Devel.Mr. Ali Kakavand Ph.D.VP & Head of Program ManagementMore ExecutivesKey CompetitorseFFECTOR TherapeuticsNASDAQ:EFTRCan-Fite BioPharmaNYSE:CANFTrevenaNASDAQ:TRVNClever LeavesNASDAQ:CLVRKinetaNASDAQ:KAView All Competitors GRAY Stock Analysis - Frequently Asked Questions How have GRAY shares performed in 2024? Graybug Vision's stock was trading at $2.86 at the beginning of 2024. Since then, GRAY stock has increased by 92.0% and is now trading at $5.49. View the best growth stocks for 2024 here. How were Graybug Vision's earnings last quarter? Graybug Vision, Inc. (NASDAQ:GRAY) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($5.32) EPS for the quarter, missing analysts' consensus estimates of ($5.18) by $0.14. When did Graybug Vision's stock split? Graybug Vision's stock reverse split on the morning of Monday, March 20th 2023. The 1-14 reverse split was announced on Monday, March 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Graybug Vision IPO? Graybug Vision (GRAY) raised $75 million in an IPO on Friday, September 25th 2020. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. SVB Leerink and Piper Sandler served as the underwriters for the IPO and Needham & Co. and Wedbush PacGrow were co-managers. How do I buy shares of Graybug Vision? Shares of GRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRAY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe World's First "$20 Trillion Drug?"Behind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graybug Vision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
